BRIEF-GSK And Vir Biotechnology Announce US Govt Agreements To Purchase Sotrovimab
Nov 17 (Reuters) - GlaxoSmithKline PLC:
* GSK - GSK AND VIR BIOTECHNOLOGY ANNOUNCE UNITED STATES GOVERNMENT AGREEMENTS TO PURCHASE SOTROVIMAB, A COVID-19 TREATMENT
* GSK - US GOVERNMENT CONTRACTS FOR APPROXIMATELY $1 BLN (USD) NOW IN PLACE TO PURCHASE SOTROVIMAB, FURTHER EXPANDING ACCESS NATIONWIDE
* GSK - THIS BRINGS TOTAL NUMBER OF DOSES SECURED THROUGH BINDING AGREEMENTS TO MORE THAN 750,000 GLOBALLY
* GSK - IN VITRO DATA INDICATE SOTROVIMAB MAINTAINS ACTIVITY AGAINST DELTA VARIANT OF CONCERN AND OTHER VARIANTS BEING MONITORED
* GSK - GSK WILL SUPPLY THESE DOSES TO US GOVERNMENT BY DECEMBER 17, 2021
* GSK - IN ADDITION TO DOSES THAT WILL BE SUPPLIED THIS YEAR, US GOVERNMENT WILL HAVE OPTION TO PURCHASE ADDITIONAL DOSES THROUGH MARCH 2022. Further company coverage:
